Effect of dietary lycopene on inflammatory marker in patients of heart failure


  • Asutosh Prafulchandra Chauhan Department of Biochemistry, GMERS Medical College, Gotri, Vadodara, Gujarat
  • Pankil K. Shah Department of Biochemistry, GMERS Medical College, Gotri, Vadodara, Gujarat




Heart failure, Inflammatory biomarkers, CRP, Lycopene


Background: Heart failure (HF), often referred to as chronic heart failure (CHF), occurs when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Patients with HF are characterized by systemic inflammation, as evident by raised circulating levels of several inflammatory cytokines with increasing levels according to the degree of disease severity. Inflammation occurs in the vasculature as a response to injury, lipid peroxidation, and perhaps infection. Inflammation can be a significant contributor in the pathophysiology of HF. Antioxidants may slow the progression of HF because of their ability to inhibit damaging inflammatory processes. The purpose of this study was to test a dietary intervention in patients with HF to assess the effect of dietary lycopene on biomarkers of inflammation.

Methods: Sixty participants with HF were randomly assigned to 1 of 2 groups: lycopene intervention and non-intervention. The lycopene intervention group received 27.212 mg of lycopene intake per day by drinking 1 serving (243 gm) of tomato soup for 30 days. We obtained serum lycopene, and C-reactive protein (CRP), to determine the impact of the intervention.

Results: Plasma lycopene levels increased in the intervention group compared with the usual group (0.50 µmol/L to 0.75 µmol/L, P = 0.002; 0.55 µmol/L to 0.57 µmol/L). C-reactive protein levels decreased significantly in the intervention group in both women and men. The pre-intervention and post-intervention CRP level for women was 15.37 ± 1.46 mg/dL and 8.32 ± 1.11 mg/dl respectively and for men was 15.05 ± 2.58 mg/dL and 8.14 ± 1.49 mg/dL respectively.

Conclusions: These findings suggest that the antioxidants in a 30-day intervention of tomato soup significantly decreases CRP levels in a sample of female and male patients with HF.  



Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure - associated hospitalizations in the united states. J Am Coll Cardiol. 2013;61:1259-67.

Hak AE, Stampfer MJ, Campos H. Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of us male physicians. Circulation. 2003;108:802-7.

Sesso HD, Buring JE, Norkus EP, Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am J Clin Nutr. 2004;79:47-53.

Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr. 2000;19:563-9.

Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JC. Serum carotenoids and atherosclerosis. The Rotterdam Study. Atherosclerosis. 2000;148:49-56.

Heymans S, Hirsch E, Anker SD. Inflammation as a therapeutic target in cardiac failure? A scientific statement from the Translational Research Committee of the Cardiac Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119-29.

Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9C-16C. Discussion 38C-40C.

Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? Int J Inflam. 2011;2011:514623.

Rissanen TH, Voutilainen S, Nyyssonen K, Salonen R, Kaplan GA, Salonen JT. Serum lycopene concentrations and carotid atherosclerosis: The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2003;77:133-8.

Mak S, Newton GE. The oxidative stress hypothesis of congestive cardiac failure: radical thoughts. Chest. 2001;120:2035-46.

Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and cardiac failure. Curr Pharm Des. 2004;10:1699-711.

Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc Drugs Ther. 2007;21:195-210.

Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med. 2000;28:1780-94.

Trachtenberg BH, Hare JM. Biomarkers of oxidative stress in cardiac failure. Heart Fail Clin. 2009;5:561-77.

Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44-84.

Levitan EB, Wolk A, Mittleman MA. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of cardiac failure in men aged 45 to 79 years. Am J Cardiol. 2009;104:1416-20.

Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Plasma vitamin c predicts incident cardiac failure in men and women in European Prospective Investigation Into Cancer and Nutrition-Norfolk Prospective Study. Am Heart J. 2011;162:246-53.

Arab L, Steck S. Lycopene and cardiovascular disease. Am J Clin Nutr. 2000;71:1691S-7S.

Kohlmeier L, Hastings SB. Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Am J Clin Nutr. 1995;62:1370S-6S.

Polidori MC, Savino K, Alunni G. Plasma lipophilic antioxidants and malondialdehyde in congestive cardiac failure patients relationship to disease severity. Free Radic Biol Med. 2002;32:148-52.

Polidori MC, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive cardiac failure are correlated with antioxidant status and disease severity. J Card Fail. 2004;10:334-8.

Martha J, Terry A, Gregory V, Rachel E, Steven J, Debra K. Lycopene dietary intervention a pilot study in patients with heart failure. J Cardiovasc Nurs. 2015;30:205-12.

Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-8.

Testa G, Cacciatore F, Galizia G. Waist circumference but not body mass index predicts long-term mortality in elderly subjects with chronic cardiac failure. J Am Geriatr Soc. 2010;58:1433-40.

Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of cardiac failure. Circulation. 2010;121:237-44.

Presnell K, Pells J, Stout A, Musante G. Sex differences in the relation of weight loss self-efficacy, binge eating, and depressive symptoms to weight loss success in a residential obesity treatment program. Eat Behav. 2008;9:170-80.

Fabricatore AN, Wadden TA, Moore RH, Butryn ML, Heymsfield SB, Nguyen AM. Predictors of attrition and weight loss success: results from a randomized controlled trial. Behav Res Ther. 2009;47:685-91.

Worcester MU, Murphy BM, Mee VK, Roberts SB, Goble AJ. Cardiac rehabilitation programmes: predictors of nonattendance and drop-out. Eur J Cardiovasc Prev Rehabil. 2004;11:328-35.

Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.

Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and cardiac failure. Eur J Intern Med. 2004;15:523-8.

Patel VB, Robbins MA, Topol EJ. C-reactive protein: a ‘goldenmarker’ for inflammation and coronary artery disease. Cleve Clin J Med. 2001;68:521-4, 527-34.

Michowitz Y, Arbel Y, Wexler D. Predictive value of high sensitivity CRP in patients with diastolic cardiac failure. Int J Cardiol. 2008;125:347-51.

Romeo R, Scalisi C, Tafuri L, Romeo A, Maugeri D, Sorace R. Different characteristics of chronic cardiac failure (CHF) in elderly diabetics and non-diabetics. Arch Gerontol Geriatr. 2009;1:101-4.

Anand IS, Latini R, Florea VG. C-reactive protein in cardiac failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428-34.

Agarwal A, Shen H, Agarwal S, Rao AV. Lycopene content of tomato products: its stability, bioavailability and in vivo antioxidant properties. J Med Food. 2001;4:9-15.

Poland B, Frohlich K, Haines RJ, Mykhalovskiy E, Rock M, Sparks R. The social context of smoking: the next frontier in tobacco control? Tob Control. 2006;15:59-63.

Hadley CW, Clinton SK, Schwartz SJ. The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. J Nutr. 2003;133:727-32.

He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Dietary sodium intake and incidence of congestive cardiac failure in overweight us men and women: First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med. 2002;162:1619-24.

He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999;282:2027-34.

Bentley B, DeJong MJ, Moser DK, Peden AR. Factors related to nonadherence to low sodium diet recommendations in cardiac failure patients. Eur J Cardiovasc Nurs. 2005;4:331-6.




How to Cite

Chauhan, A. P., & Shah, P. K. (2017). Effect of dietary lycopene on inflammatory marker in patients of heart failure. International Journal of Research in Medical Sciences, 3(11), 3182–3186. https://doi.org/10.18203/2320-6012.ijrms20151159



Original Research Articles